Compare
Keros Therapeutics, Inc. vs Arcus Biosciences, Inc. vs Akebia Therapeutics, Inc. vs Anaptysbio, Inc
| Latest fiscal year | Keros Therapeutics, Inc. KROS | Arcus Biosciences, Inc. RCUS | Akebia Therapeutics, Inc. AKBA | Anaptysbio, Inc ANAB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $244.06M | $247.00M | $236.20M | $234.60M |
| Revenue growth (YoY) | n/m | -4.3% | +47.5% | +157.0% |
| Gross margin | n/a | n/a | 83.3% (computed) | n/a |
| Operating margin | 27.7% | -156.3% | 9.9% | 20.4% |
| Net margin | 35.7% | -142.9% | -2.3% | -5.6% |
| Net income | $87.01M | -$353.00M | -$5.34M | -$13.23M |
| EPS (Diluted) | $2.30 | -$3.29 | -$0.02 | -$0.46 |
| Operating cash flow | $107.50M | -$482.00M | $67.99M | $19.70M |
| Free cash flow | $105.95M | -$484.00M | $67.70M | $19.61M |
| Cash & equivalents | $287.42M | $222.00M | $184.84M | $238.20M |
| Total assets | $338.02M | $1.14B | $376.56M | $364.39M |
| Total liabilities | $34.89M | n/a | $343.95M | n/a |
| Shareholders' equity | $303.13M | $631.00M | $32.61M | $37.21M |
| Return on year-end equity | 28.7% | -55.9% | -16.4% | -35.6% |
| Shares outstanding | 19.54M | 125.30M | 265.42M | 28.02M |
Revenue, most recent five fiscal years
| Fiscal year | Keros Therapeutics, Inc. | Arcus Biosciences, Inc. | Akebia Therapeutics, Inc. | Anaptysbio, Inc |
|---|---|---|---|---|
| Latest | $244.06M Ended 2025-12-31 | $247.00M Ended 2025-12-31 | $236.20M Ended 2025-12-31 | $234.60M Ended 2025-12-31 |
| 1 year earlier | $3.55M Ended 2024-12-31 | $258.00M Ended 2024-12-31 | $160.18M Ended 2024-12-31 | $91.28M Ended 2024-12-31 |
| 2 years earlier | $151.0K Ended 2023-12-31 | $117.00M Ended 2023-12-31 | $194.62M Ended 2023-12-31 | $17.16M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $112.00M Ended 2022-12-31 | $292.48M Ended 2022-12-31 | $10.29M Ended 2022-12-31 |
| 4 years earlier | $20.10M Ended 2021-12-31 | $383.00M Ended 2021-12-31 | $211.65M Ended 2021-12-31 | $63.17M Ended 2021-12-31 |